309 related articles for article (PubMed ID: 27637911)
1. Concomitant Use of Proton-Pump Inhibitors and Clopidogrel Increases the Risk of Adverse Outcomes in Patients With Ischemic Stroke Carrying Reduced-Function CYP2C19*2.
Yi X; Han Z; Zhou Q; Cheng W; Lin J; Wang C
Clin Appl Thromb Hemost; 2018 Jan; 24(1):55-62. PubMed ID: 27637911
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
3. Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
Yi X; Lin J; Wang Y; Zhou Q; Wang C; Cheng W; Chi L
J Atheroscler Thromb; 2016 Oct; 23(10):1188-1200. PubMed ID: 26961113
[TBL] [Abstract][Full Text] [Related]
4. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
5. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
[TBL] [Abstract][Full Text] [Related]
6. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
[TBL] [Abstract][Full Text] [Related]
7. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
[TBL] [Abstract][Full Text] [Related]
9. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
[TBL] [Abstract][Full Text] [Related]
10. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Han SW; Kim YJ; Ahn SH; Seo WK; Yu S; Oh SH; Kim YN; Lee KY;
Int J Stroke; 2016 Jun; 11(4):485-91. PubMed ID: 26763917
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Wang Y; Cai H; Zhou G; Zhang Z; Liu X
J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
[TBL] [Abstract][Full Text] [Related]
12. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.
Tran M; Tafreshi J; Pai RG
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037
[TBL] [Abstract][Full Text] [Related]
13. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Biswas M; Rahaman S; Biswas TK; Ibrahim B
Int J Clin Pharm; 2021 Oct; 43(5):1360-1369. PubMed ID: 33774763
[TBL] [Abstract][Full Text] [Related]
14. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.
Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ
J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
16. Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).
Bundhun PK; Teeluck AR; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):3. PubMed ID: 28056809
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
[TBL] [Abstract][Full Text] [Related]
18. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Yi X; Wang Y; Lin J; Cheng W; Zhou Q; Wang C
Clin Appl Thromb Hemost; 2017 Oct; 23(7):761-768. PubMed ID: 27233747
[TBL] [Abstract][Full Text] [Related]
19. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S
Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
